INTANGIBLE ASSETS (Tables)

6 Months Ended

Jun. 30, 2019

Intangible Assets, Net (Excluding Goodwill) [Abstract]

Schedule of intangible assets

The following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets as of June 30, 2019 and December 31, 2018:

       

	June 30, 2019
	Gross Carrying Amount		Accumulated Amortization			Net Amount		Weighted-Average Remaining Amortization Period (yrs.)
Amortizable intangible assets:
Approved hormone therapy drug candidate patents		2,962,563		(370,338	)		2,592,225		13.5
Hormone therapy drug candidate patents (pending)		1,833,584		—			1,833,584		n/a
Non-amortizable intangible assets:
Multiple trademarks		262,305		—			262,305		indefinite
TOTAL	$	5,058,452	$	(370,338	)	$	4,688,114

        

	December 31, 2018
	Gross Carrying Amount		Accumulated Amortization			Net Amount		Weighted-Average Remaining Amortization Period (yrs.)
Amortizable intangible assets:
OPERA® software patent	$	31,951	$	(10,484	)	$	21,467		10.75
Development costs of corporate website		91,743		(91,743	)		—		n/a
Approved hormone therapy drug candidate patents		2,234,129		(282,485	)		1,951,644			14
Hormone therapy drug candidate patents (pending)		1,855,279		—			1,855,279		n/a
Non-amortizable intangible assets:
Multiple trademarks		264,289		—			264,289		indefinite
TOTAL	$	4,477,391	$	(384,712	)	$	4,092,679

Schedule of estimated amortization expense

 

Year Ending December 31,		Estimated Amortization
	2019(6 months)	$	96,008
	2020	$	196,017
	2021	$	196,017
	2022	$	196,017
	2023	$	196,017